# Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

> **NCT03767543** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 265 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010

## Key facts

- **NCT ID:** NCT03767543
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-11
- **Primary completion:** 2020-10-23
- **Final completion:** 2020-10-23
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2022-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03767543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03767543, "Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT03767543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*